ABBV US00287Y1091

Report

Delayed Nyse - 05/20 04:03:24 pm
151.01	USD		-0.47%

05/20	Berenberg Bank Adjusts AbbVie's Price Target to $135 From $115, Maintains Hold Rating	MT
05/20	AbbVie Says It Has Filed New Drug Application With FDA for Advanced Parkinson's Disease Treatment	MT
05/20	AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease	PR

Calendar

Event chart ABBVIE INC.

Upcoming events on ABBVIE INC.

06/01/22 \| 11:00am		Bernstein Strategic Decisions Conference
07/29/22		Interim 2022 Earnings Release (Projected)
11/04/22		Q3 2022 Earnings Release (Projected)
01/27/23		FY 2022 Earnings Release (Projected)
04/27/23		Q1 2023 Earnings Release (Projected)

Past events on ABBVIE INC.

05/06/22 \| 10:00am		Annual General Meeting
05/04/22 \| 12:34pm		Association for Research in Vision and Ophthalmology Meeting
05/02/22 \| 02:30pm		Association for research in vision and ophthalmology meeting - posterboard number: 1810 – f0426
05/02/22 \| 02:30pm		Association for research in vision and ophthalmology meeting - posterboard number: 1815 – f0431
05/02/22 \| 02:30pm		Association for research in vision and ophthalmology meeting - posterboard number: 1808 – f0424
05/02/22 \| 02:30pm		Association for research in vision and ophthalmology meeting - posterboard number: 1812 – f0428
05/02/22 \| 02:30pm		Association for research in vision and ophthalmology meeting - posterboard number: 1814 – f0430
05/02/22 \| 02:30pm		Association for research in vision and ophthalmology meeting - posterboard number: 1811 – f0427
04/29/22 \| 09:00am		Q1 2022 Earnings Call
04/29/22 \| 07:43am		Q1 2022 Earnings Release

Past dividends on ABBVIE INC.

04/13/22		Quarterly 1.41 USD
01/13/22		Quarterly 1.41 USD
10/14/21		Quarterly 1.3 USD
07/14/21		Quarterly 1.3 USD
04/14/21		Quarterly 1.3 USD
01/14/21		Quarterly 1.3 USD
10/14/20		Quarterly 1.18 USD
07/14/20		Quarterly 1.18 USD
04/14/20		Quarterly 1.18 USD
01/14/20		Quarterly 1.18 USD

Annual results

Fiscal Period : December		2017	2018	2019	2020	2021	2022
Sales M $	Released Forecast Spread	28 216 28 011 0,73%	32 733 32 714 0,06%	33 266 33 255 0,03%	45 784 45 637 0,32%	56 122 56 238 -0,21%	59 610
Operating income (EBITDA) M $	Released Forecast Spread	12 452 12 514 -0,49%	16 358 15 640 4,6%	17 747 16 811 5,6%	22 642 22 766 -0,54%	29 018 29 168 -0,51%	31 731
Operating profit (EBIT) M $	Released Forecast Spread	12 027 11 982 0,37%	14 593 14 695 -0,69%	15 730 15 736 -0,04%	21 976 21 832 0,66%	28 215 28 167 0,17%	30 788
Pre-Tax Profit (EBT) M $	Released Forecast Spread	7 727 8 862 -13%	5 197 10 814 -52%	8 426 12 085 -30%	3 398 14 347 -76%	12 989 12 579 3,3%	19 352
Net income M $	Released Forecast Spread	5 309 7 099 -25%	5 687 10 124 -44%	7 882 7 753 1,7%	4 616 7 357 -37%	11 542 11 140 3,6%	16 897
EPS $	Released Forecast Spread	3,30 4,41 -25%	3,66 6,50 -44%	5,28 5,23 0,97%	2,72 4,27 -36%	6,45 6,25 3,3%	9,65
Announcement Date		01/26/2018	01/25/2019	02/07/2020	02/03/2021	02/02/2022	-

Quarterly results

Fiscal Period : December

2021 Q1

2021 Q2

2021 Q3

2021 Q4

2022 Q1

2022 Q2

Sales
M $

Released
Forecast
Spread

12 935
12 775
1,3%

13 959
13 636
2,4%

14 342
14 299
0,30%

14 886
14 959
-0,49%

13 538
13 613
-0,55%

14 635

Operating income
(EBITDA)
M $

Released
Forecast
Spread

6 808
6 519
4,4%

7 145
7 061
1,2%

7 559
7 288
3,7%

7 506
7 457
0,66%

7 301
7 115
2,6%

8 218

Operating profit
(EBIT)
M $

Released
Forecast
Spread

6 602
6 366
3,7%

6 944
6 904
0,57%

7 336
7 134
2,8%

7 333
7 277
0,77%

7 103
6 972
1,9%

7 525

Net income
M $

Released
Forecast
Spread

3 553
1 823
95%

766
2 422
-68%

3 179
3 163
0,51%

4 044
3 810
6,2%

4 490
3 473
29%

3 864

EPS
$

Released
Forecast
Spread

1,99
1,26
58%

0,42
1,58
-73%

1,78
1,99
-11%

2,26
2,10
7,8%

2,51
2,03
23%

2,29

Announcement Date

04/30/2021

07/30/2021

10/29/2021

02/02/2022

04/29/2022

Previous year

Next Year

Upcoming sector events for ABBVIE INC.

07/19/22 \| 06:25am		JOHNSON & JOHNSON : Interim 2022 Earnings Release
07/21/22		ROCHE HOLDING AG : Interim 2022 Earnings Release
08/02/22		PFIZER INC. : Interim 2022 Earnings Release (Projected)
08/04/22 \| 06:25am		ELI LILLY AND COMPANY : Interim 2022 Earnings Release
10/18/22		JOHNSON & JOHNSON : Q3 2022 Earnings Release
10/18/22		ROCHE HOLDING AG : Q3 2022 Sales and Revenue Release
11/01/22		PFIZER INC. : Q3 2022 Earnings Release (Projected)
11/01/22 \| 05:25am		ELI LILLY AND COMPANY : Q3 2022 Earnings Release
01/24/23		JOHNSON & JOHNSON : FY 2022 Earnings Release (Projected)
01/31/23		PFIZER INC. : FY 2022 Earnings Release (Projected)

More events

Past sector events for ABBVIE INC.

05/03/22 \| 06:45am		PFIZER INC. : Q1 2022 Earnings Release
04/28/22 \| 06:25am		ELI LILLY AND COMPANY : Q1 2022 Earnings Release
04/25/22 \| 01:00am		ROCHE HOLDING AG : Q1 2022 Sales and Revenue Release
04/19/22 \| 06:25am		JOHNSON & JOHNSON : Q1 2022 Earnings Release
02/08/22 \| 06:45am		PFIZER INC. : FY 2021 Earnings Release
02/03/22 \| 06:25am		ELI LILLY AND COMPANY : FY 2021 Earnings Release
02/03/22 \| 01:00am		ROCHE HOLDING AG : FY 2021 Earnings Release
01/25/22 \| 06:25am		JOHNSON & JOHNSON : FY 2021 Earnings Release
11/02/21 \| 05:45am		PFIZER INC. : Q3 2021 Earnings Release
10/26/21 \| 06:25am		ELI LILLY AND COMPANY : Q3 2021 Earnings Release

More events

Analysis

J&J settles West Virginia opioid litigation for $99 million